These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. Kuba K; Yamaguchi T; Penninger JM Front Immunol; 2021; 12():732690. PubMed ID: 35003058 [TBL] [Abstract][Full Text] [Related]
3. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Mehdipour AR; Hummer G Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171 [TBL] [Abstract][Full Text] [Related]
4. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Lin C; Li Y; Zhang Y; Liu Z; Mu X; Gu C; Liu J; Li Y; Li G; Chen J Signal Transduct Target Ther; 2021 May; 6(1):198. PubMed ID: 34006835 [No Abstract] [Full Text] [Related]
5. Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor. Delgado JM; Duro N; Rogers DM; Tkatchenko A; Pandit SA; Varma S Proteins; 2021 Sep; 89(9):1134-1144. PubMed ID: 33864655 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540 [TBL] [Abstract][Full Text] [Related]
7. Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET. Cecon E; Dam J; Jockers R STAR Protoc; 2022 Mar; 3(1):101024. PubMed ID: 34841271 [TBL] [Abstract][Full Text] [Related]
8. Structural basis of severe acute respiratory syndrome coronavirus 2 infection. Ge J; Zhang S; Zhang L; Wang X Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231 [TBL] [Abstract][Full Text] [Related]
9. Molecular simulation studies of the interactions between the human/pangolin/cat/bat ACE2 and the receptor binding domain of the SARS-CoV-2 spike protein. Ma S; Li H; Yang J; Yu K Biochimie; 2021 Aug; 187():1-13. PubMed ID: 33984400 [TBL] [Abstract][Full Text] [Related]
10. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines. Li J; Wang P; Tracey KJ; Wang H Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis. Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423 [TBL] [Abstract][Full Text] [Related]
12. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. Choudhury A; Mukherjee S J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269 [TBL] [Abstract][Full Text] [Related]
13. Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain. Low-Gan J; Huang R; Kelley A; Jenkins GW; McGregor D; Smider VV Biochem J; 2021 Oct; 478(19):3671-3684. PubMed ID: 34558627 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy. Chen J; Li S; Lei Z; Tang Q; Mo L; Zhao X; Xie F; Zi D; Tan J Int J Biol Sci; 2021; 17(11):2957-2969. PubMed ID: 34345219 [TBL] [Abstract][Full Text] [Related]
15. Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins. Zang Y; Li X; Zhao Y; Wang H; Hao D; Zhang L; Yang Z; Yuan X; Zhang S Phys Chem Chem Phys; 2021 Jun; 23(24):13752-13759. PubMed ID: 34132301 [TBL] [Abstract][Full Text] [Related]
16. Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein. Heinzelman P; Romero PA PLoS One; 2021; 16(5):e0251585. PubMed ID: 33979391 [TBL] [Abstract][Full Text] [Related]
17. Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection. Ren W; Zhu Y; Lan J; Chen H; Wang Y; Shi H; Feng F; Chen DY; Close B; Zhao X; Wu J; Tian B; Yuan Z; Zhou D; Saeed M; Wang X; Zhang R; Ding Q J Virol; 2022 Jan; 96(1):e0149221. PubMed ID: 34668773 [TBL] [Abstract][Full Text] [Related]
18. Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1. Yang J; Perez EA; Hou C; Zhang P; Van Scoyk M; Winn RA; Rong L; Liu J Front Immunol; 2021; 12():648815. PubMed ID: 34305888 [TBL] [Abstract][Full Text] [Related]
19. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993 [TBL] [Abstract][Full Text] [Related]
20. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Liu H; Zhang Q; Wei P; Chen Z; Aviszus K; Yang J; Downing W; Jiang C; Liang B; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G Cell Res; 2021 Jun; 31(6):720-722. PubMed ID: 33893398 [No Abstract] [Full Text] [Related] [Next] [New Search]